PANoptosis is a unique innate immune inflammatory lytic cell death pathway initiated by an innate immune sensor and driven by caspases and RIPKs. As a distinct pathway, the execution of PANoptosis cannot be hindered by targeting other cell death pathways, such as pyroptosis, apoptosis, or necroptosis. Instead, targeting key PANoptosome components can serve as a strategy to prevent this form of cell death. Given the physiological relevance in several diseases, PANoptosis is a pivotal therapeutic target. Notably, previous research has primarily focused on the role of PANoptosis in cancer and infectious and inflammatory diseases. By contrast, its role in cardiovascular diseases has not been comprehensively discussed. Here, we review the available evidence on PANoptosis in cardiovascular diseases, including cardiomyopathy, atherosclerosis, myocardial infarction, myocarditis, and aortic aneurysm and dissection, and explore a variety of agents that target PANoptosis, with the overarching goal of providing a novel complementary approach to combatting cardiovascular diseases.

PANoptosis 是一种独特的先天免疫炎症溶解细胞死亡途径，由先天免疫传感器启动并由 caspase 和 RIPK 驱动。作为一种独特的途径，PANoptosis 的执行不能通过针对其他细胞死亡途径（例如细胞焦亡、细胞凋亡或坏死性凋亡）来阻碍。相反，针对关键的 PANoptosome 成分可以作为预防这种形式的细胞死亡的策略。鉴于多种疾病的生理相关性，全性下垂是一个关键的治疗靶点。值得注意的是，之前的研究主要集中在 PANoptosis 在癌症以及传染病和炎症性疾病中的作用。相比之下，它在心血管疾病中的作用尚未得到全面讨论。在这里，我们回顾了心血管疾病中 PANoptosis 的现有证据，包括心肌病、动脉粥样硬化、心肌梗塞、心肌炎、主动脉瘤和夹层，并探索了多种针对 PANoptosis 的药物，总体目标是提供一种新的补充方法对抗心血管疾病。